Domestic pharmaceutical firms to nurture cGMP professionals

Korean companies will be able to bet on the possibility of mutual recognition arrangement (MRA) on generic drugs following the free trade agreement (FTA) ratification with the United States.

However, there are growing concerns that domestic drug makers should be keen on the new construction of cGMP plant, while neglecting the nurture of professional people to run the plant.

“Korean pharm...